Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RVMD – Revolution Medicines, Inc.

Revolution Medicines, Inc.
RVMD
$41.29
Name : Revolution Medicines, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,690,074,112.00
EPSttm : -4.01
finviz dynamic chart for RVMD
Revolution Medicines, Inc.
$41.29
2.70%
$1.08

Float Short %

11.66

Margin Of Safety %

Put/Call OI Ratio

0.46

EPS Next Q Diff

-0.04

EPS Last/This Y

-1.07

EPS This/Next Y

-0.33

Price

40.2

Target Price

72.36

Analyst Recom

1.08

Performance Q

2.5

Relative Volume

0.69

Beta

1.1

Ticker: RVMD




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07RVMD37.640.990.0020418
2025-05-08RVMD41.910.990.0720468
2025-05-09RVMD40.450.980.0020577
2025-05-12RVMD41.90.890.0821615
2025-05-13RVMD39.970.870.1021864
2025-05-14RVMD39.50.870.5221978
2025-05-15RVMD39.310.868.8222155
2025-05-16RVMD39.470.870.0022276
2025-05-19RVMD39.920.971.9818818
2025-05-20RVMD40.510.971.2018852
2025-05-21RVMD38.740.97100.0018969
2025-05-22RVMD38.790.9762.6718987
2025-05-23RVMD39.760.995.0019135
2025-05-27RVMD36.960.991.1519132
2025-05-28RVMD37.610.980.0219194
2025-05-29RVMD39.080.690.2423333
2025-05-30RVMD39.370.650.0324796
2025-06-02RVMD40.660.540.1628324
2025-06-03RVMD40.60.490.2430915
2025-06-04RVMD40.40.460.1131877
2025-06-05RVMD40.210.460.5532007
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07RVMD37.66-50.8-288.4-4.48
2025-05-08RVMD41.91-50.8-438.2-4.48
2025-05-09RVMD40.43-40.5-134.5-4.63
2025-05-12RVMD41.88-40.5-227.2-4.63
2025-05-13RVMD39.95-38.9-137.0-4.66
2025-05-14RVMD39.46-40.5-181.5-4.63
2025-05-15RVMD39.46-38.4-197.2-4.63
2025-05-16RVMD39.49-38.4-200.0-4.65
2025-05-19RVMD39.93-38.4-211.3-4.65
2025-05-20RVMD40.47-38.4-216.0-4.65
2025-05-21RVMD38.71-38.4-139.8-4.65
2025-05-22RVMD38.81-38.4-200.5-4.65
2025-05-23RVMD39.77-38.4-231.9-4.65
2025-05-27RVMD36.97-38.4-103.4-4.65
2025-05-28RVMD37.71-38.4-225.5-4.65
2025-05-29RVMD39.08-38.4-246.9-4.65
2025-05-30RVMD39.40-38.4-208.9-4.65
2025-06-02RVMD40.67-38.4-241.2-4.65
2025-06-03RVMD40.58-38.4-195.6-4.65
2025-06-04RVMD40.38-38.4-191.5-4.65
2025-06-05RVMD40.20-38.4-192.0-4.65
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07RVMD5.3316.5810.14
2025-05-08RVMD5.3316.5810.14
2025-05-09RVMD5.3516.5810.14
2025-05-12RVMD5.3513.9110.22
2025-05-13RVMD5.3513.9110.22
2025-05-14RVMD5.3513.9110.22
2025-05-15RVMD5.3513.9110.22
2025-05-16RVMD5.4313.9110.22
2025-05-19RVMD5.4312.3210.22
2025-05-20RVMD5.4312.3210.22
2025-05-21RVMD5.4312.3210.22
2025-05-22RVMD5.4312.3210.22
2025-05-23RVMD5.4312.3210.22
2025-05-27RVMD5.43-0.8810.22
2025-05-28RVMD5.43-0.8811.66
2025-05-29RVMD5.43-0.8811.66
2025-05-30RVMD5.43-0.8811.66
2025-06-02RVMD5.43-0.5711.66
2025-06-03RVMD5.43-0.5711.66
2025-06-04RVMD5.43-0.5711.66
2025-06-05RVMD5.43-0.5711.66
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.13

Avg. EPS Est. Current Quarter

-1.12

Avg. EPS Est. Next Quarter

-1.17

Insider Transactions

5.43

Institutional Transactions

-0.57

Beta

1.1

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

25

Sentiment Score

88

Actual DrawDown %

35.6

Max Drawdown 5-Year %

-73.3

Target Price

72.36

P/E

Forward P/E

PEG

P/S

P/B

3.6

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y​

-4.65

EPS Next Y. (Est.)

-4.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.69

Return on Equity vs Sector %

-57.6

Return on Equity vs Industry %

-39.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.17

EBIT Estimation

-192
Revolution Medicines, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 616
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading